40 patents
Page 2 of 2
Utility
Inhibiting ubiquitin specific peptidase 30
15 Feb 22
Justin Caravella, Bingsong Han, Cuixian Liu, Stephanos Ioannidis, Alexandre Joseph Buckmelter, David James Richard, Matthew W. Martin, Steven Mischke, Scot Mente
Filed: 5 Oct 18
Utility
Purinones as ubiquitin-specific protease 1 inhibitors
2 Nov 21
Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
Filed: 14 Aug 19
Utility
Tetrahydroquinoline compositions as BET bromodomain inhibitors
7 Sep 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
Filed: 28 Jan 20
Utility
Benzopiperazine compositions as BET bromodomain inhibitors
10 Aug 21
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
Filed: 12 May 20
Utility
Activating pyruvate kinase R
27 Jul 21
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 1 May 20
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
25 May 21
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 4 Jun 19
Utility
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
25 May 21
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 30 Jul 19
Utility
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
25 May 21
Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
Filed: 20 Mar 18
Utility
Activating pyruvate kinase R and mutants thereof
11 May 21
The disclosure provides chemical compounds useful as activators of PKR.
David R. Lancia, Jr., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
Filed: 19 Sep 19
Utility
Compounds and compositions for inhibition of FASN
4 May 21
Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
Filed: 20 May 20
Utility
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
30 Mar 21
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 25 Nov 19
Utility
Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
9 Feb 21
David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, Jr., David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
Filed: 13 Feb 17
Utility
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
12 Jan 21
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 12 Dec 19
Utility
Inhibiting fatty acid synthase (FASN)
28 Dec 20
The present disclosure is directed to inhibitors of FASN.
Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
Filed: 9 Oct 19
Utility
Inhibiting CREB binding protein (CBP)
21 Dec 20
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
Filed: 27 Jun 19
Utility
Compositions for activating pyruvate kinase
16 Nov 20
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
Filed: 3 Oct 19
Utility
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
19 Oct 20
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 21 Jul 19
Utility
Compounds and compositions for inhibition of FASN
12 Oct 20
Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
Filed: 9 Sep 19
Utility
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
5 Oct 20
George P. Luke, Stephen Hubbs, Matthew W. Martin, Robert Wenslow, Yawei Shi, Jun Huang
Filed: 28 Oct 19
Utility
Benzopiperazine compositions as BET bromodomain inhibitors
6 Jul 20
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
Filed: 17 Jun 19